- All
- 2026-06-11 [Thursday]
- 2026-06-12 [Friday]
- 2026-06-13 [Saturday]
- 2026-06-14 [Sunday]
- All
- A1-A (102-107)
- A1-A101
- A1-A102
- A1-A103
- A1-A104
- A1-A (105-107)
- A1-A108
- A1-A109
- A1-A110
- A2-A206
- A2-A207
- A2-A208
- A2-A213
- A2-A214
- A2-A215
- B1 Hall (Poster Area)
- B1 Hall (Exhibition Area)
2026-06-11 (Thursday)
A1-A108
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 15:05-15:13 |
Adjuvant Hyperbaric Oxygen Therapy with Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: A Pilot Study on Efficacy and Safety |
Rui An | Xijing Hospital, The Fourth Military Medical University, China |
| 2 | 15:13-15:21 |
Clinical study of TACE/HAIC combined with intra-arterial infusion of atezolizumab + bevacizumab for the treatment of medium-to-advanced HCC |
Song-Nan Zhang | Yanbian University Hospital, China |
| 3 | 15:21-15:29 |
Application of Blood Supply–Based TACE Sequential HAIC Combined with T+A in Conversion Therapy for Intermediate-Advanced HCC: A Multicenter Retrospective Study |
Jin-Long Yan | Second Affiliated Hospital of Nanchang University, China |
| 4 | 15:37-15:45 |
The redox regulation in cancer |
Jia-Lei Sun | Zhongshan Hospital, Fudan University, China |
| 5 | 15:45-15:53 |
SBRT Followed by Sintilimab and Ipilimumab-N01 Combined with HAIC for Advanced Hepatocellular Carcinoma After Failure of Prior Targeted Therapy and Immunotherapy: A Trial in Progress |
Hui Zeng | Zhuhai Dichuan Biopharmaceutical Technology Co., Ltd. |
| 6 | 15:53-16:01 |
Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm):A multicenter retrospective study |
Minghua Shao | The First Affiliated Hospital of the Army Medical University, China |
| 7 | 16:01-16:13 |
Panel Discussion |
Hyo-Cheol Kim | Seoul National University Hospital, ROK(Republic of Korea) |
